-+ 0.00%
-+ 0.00%
-+ 0.00%

Ovid Therapeutics says Series A warrants expire after $53.9 million exercise

PUBT·04/20/2026 12:17:35
Listen to the news
Ovid Therapeutics says Series A warrants expire after $53.9 million exercise
  • Ovid Therapeutics Series A Warrants from October 2025 private placement expired on April 17, 2026.
  • Investors exercised warrants into 33,597,860 common shares at USD 1.4 per share.
  • Holders also received 4,883,464 pre-funded warrants at USD 1.4 per share.
  • Transaction generated gross proceeds of about USD 53.9 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-025926), on April 20, 2026, and is solely responsible for the information contained therein.